ClinicalTrials.gg

Lung Diseases, Interstitial clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 682 studies for Lung Diseases, Interstitial across more than 10 countries. 246 are recruiting or about to start. 333 of them are mainly about Lung Diseases, Interstitial (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17. Counting its 9 narrower conditions too, such as Idiopathic Pulmonary Fibrosis: 1,662 studies, 462 open.

ClinicalTrials.gov finds 1,776 studies for Lung Diseases, Interstitial. How that becomes 679 here

This page counts the studies the registry files under Lung Diseases, Interstitial, and those it files under no condition that list Lung Diseases, Interstitialthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

  1. 1,776Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −962Filed under a narrower condition, counted on its own pageIdiopathic Pulmonary Fibrosis 469 · Pulmonary Fibrosis 183 · Granulomatosis with Polyangiitis 102 · Histiocytosis, Langerhans-Cell 80 · Sarcoidosis, Pulmonary 54 · Radiation Pneumonitis 35 · 3 more
  3. −16List Lung Diseases, Interstitial as a condition, but the registry did not file them under itMost often written as “Diffuse Interstitial Lung Disease” (2), “Interstitial Lung Disease Due to Systemic Disease” (2), and “Pneumonia, Interstitial Plasma Cell” (1). The registry filed them under other conditions only, most often Lung Diseases (3) and Pulmonary Arterial Hypertension (3).
  4. −121Match it another way49 name it in the title, 2 in a keyword, and 70 by a synonym or other text the search reads.
  5. 677Counted here and found by its search38 of them list Lung Diseases, Interstitial in their own words; the registry filed them under no condition.
  6. +2
    Counted here, but its search does not find them
  7. 679The count on this page

Status

Completed
250
Recruiting
173
Status unknown
96
Not yet recruiting
60
Active, not recruiting
41
Terminated
38

Phase

Phase 2
110
Phase 3
66
Phase 1
35
Phase 4
28
Early Phase 1
4

Where

United States
201
United Kingdom
91
France
90
China
76
Germany
66
Canada
64

Who develops what

Add Lung Diseases, Interstitial to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 15 programs from 15 companies, 4 with this as their studies’ main aim; 5 with a live phase 3 study; 5 primary completions in the next 12 months. Compare Boehringer Ingelheim, Bristol-Myers Squibb and Galderma Group here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

None given by two companies or more yet.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
nerandomilastApproved: US 2025 · EU 2026☆ Track4 live phase-3 studies: NCT07201922, NCT06806592, NCT07540988Boehringer Ingelheim
treprostinil hexadecyl ester☆ Track3 live phase-3 studies: NCT07234032, NCT07805785, NCT07179380Insmed Incorporated
belimumabApproved: EU 2011☆ Track3 live phase-3 studies: NCT06716606, NCT05878717, NCT06572384GlaxoSmithKline

The 3 in phase 3 with the nearest primary completion, of 15 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (5)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Dec 2026 est.mosliciguat · Pulmovant, Inc. · Phase 2 named, not the main aimNCT07333183 A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD — primary endpoint: Incidence and nature of participant TEAEs, SAEs, and AEs leading to discontinuation · 20 enrolled
  • Mar 2027 est.ROC-101 · AllRock Bio, Inc. · Phase 2 named, not the main aimNCT07175038 A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY) — primary endpoint: Change in Pulmonary Vascular Resistance (PVR) from Baseline versus at 24 weeks · 40 enrolled
  • 15 Apr 2027 est.nerandomilast · Boehringer Ingelheim · Phase 3 main aimNCT06806592 A Study to Test Whether Nerandomilast Helps People With Lung Fibrosis Related to Rheumatic Diseases — primary endpoint: Absolute change from baseline in quantitative interstitial lung disease (QILD) score [%] on high-resolution computed tomography (HRCT) at Week 26 · 414 enrolled

2 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Lung Diseases, Interstitial studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Corticosteroids 4 open · Tyrosine kinase inhibitors (TKIs) 2 open · JAK inhibitors 2 open · Alkylating agents 1 open · Endothelin receptor antagonists 7

Coming up

85studies finish main data collection within a year5 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 173 Lung Diseases, Interstitial studies recruiting now, 108 (62%) set no upper age limit and 25 (14%) stop at 75 or younger. 13 (8%) take children under 18. 0 (0%) are for women only and 1 (1%) for men only; 21 (12%) take healthy volunteers.

Recruiting studies that take each age, of 173
AgeWomenMen
1012 (7%)12 (7%)
18147 (85%)147 (85%)
30152 (88%)152 (88%)
40168 (97%)168 (97%)
50169 (98%)170 (98%)
65165 (95%)166 (96%)
75162 (94%)163 (94%)
85130 (75%)131 (76%)

Across all 682 studies, recruiting or not: 16% stop at 75 or younger and 5% at 65; 10% take children; <1% are for women only and 1% for men only; 13% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Lung Diseases, Interstitial studies take

Of 53 phase 2 interventional studies under Lung Diseases, Interstitial, half reached primary completion within 51 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 251 mo30–71 · 53 studies——
Phase 333 mo29–61 · 36 studies——
Interventional, no phase27 mo14–44 · 119 studies—27 mo14–46 · 114 studies
Observational55 mo31–83 · 132 studies—72 mo35–274 · 111 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 682. Browse all 682 → or search them.